Greg L Plosker

Summary

Affiliation: Adis International Inc
Country: USA

Publications

  1. doi request reprint Lurasidone : in the treatment of schizophrenia
    Mark Sanford
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay North Shore, 0754, Auckland, New Zealand
    CNS Drugs 27:67-80. 2013
  2. doi request reprint Perampanel: as adjunctive therapy in patients with partial-onset seizures
    Greg L Plosker
    Adis, 41 Centorian Drive, Mairangi Bay, North Shore, Private Bag 65901, 0754 Auckland, New Zealand
    CNS Drugs 26:1085-96. 2012
  3. doi request reprint Gabapentin enacarbil: in patients with restless legs syndrome
    Lesley J Scott
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754 Auckland, New Zealand
    CNS Drugs 26:1073-83. 2012
  4. doi request reprint Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome)
    Greg L Plosker
    Adis, Mairangi Bay, North Shore, Private Bag, Auckland, New Zealand
    CNS Drugs 26:993-1001. 2012
  5. doi request reprint Sublingual zolpidem (Edluar™; Sublinox™)
    Lily P H Yang
    Adis, Private Bag, Mairangi Bay, North Shore, Auckland, New Zealand
    CNS Drugs 26:1003-10. 2012
  6. ncbi request reprint Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels
    Gillian M Keating
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 65:521-36. 2005
  7. doi request reprint Eprosartan: a review of its use in hypertension
    Greg L Plosker
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 69:2477-99. 2009
  8. ncbi request reprint Dabigatran etexilate
    Mark Sanford
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 68:1699-709. 2008
  9. ncbi request reprint Selegiline transdermal system in major depressive disorder: profile report
    James E Frampton
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 21:521-4. 2007
  10. ncbi request reprint Zolpidem extended-release
    Marit D Moen
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    CNS Drugs 20:419-26; discussion 427-8. 2006

Collaborators

Detail Information

Publications86

  1. doi request reprint Lurasidone : in the treatment of schizophrenia
    Mark Sanford
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay North Shore, 0754, Auckland, New Zealand
    CNS Drugs 27:67-80. 2013
    ..Lurasidone was associated with a low risk of QT interval prolongation, weight gain, metabolic disturbances and hyperprolactinaemia. Further trials against other antipsychotics are needed to fully evaluate its efficacy and tolerability...
  2. doi request reprint Perampanel: as adjunctive therapy in patients with partial-onset seizures
    Greg L Plosker
    Adis, 41 Centorian Drive, Mairangi Bay, North Shore, Private Bag 65901, 0754 Auckland, New Zealand
    CNS Drugs 26:1085-96. 2012
    ..On the basis of its overall clinical profile and unique mechanism of action, perampanel is a useful adjunctive treatment option in patients with refractory partial-onset seizures...
  3. doi request reprint Gabapentin enacarbil: in patients with restless legs syndrome
    Lesley J Scott
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754 Auckland, New Zealand
    CNS Drugs 26:1073-83. 2012
    ..The most common treatment-emergent adverse events were somnolence/sedation and dizziness. Most adverse events were of mild to moderate severity, with relatively few patients discontinuing treatment because of an adverse event...
  4. doi request reprint Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome)
    Greg L Plosker
    Adis, Mairangi Bay, North Shore, Private Bag, Auckland, New Zealand
    CNS Drugs 26:993-1001. 2012
    ..Stiripentol is an important addition to the limited treatment options available for the management of patients with SMEI...
  5. doi request reprint Sublingual zolpidem (Edluar™; Sublinox™)
    Lily P H Yang
    Adis, Private Bag, Mairangi Bay, North Shore, Auckland, New Zealand
    CNS Drugs 26:1003-10. 2012
    ..Sublingual zolpidem was generally well tolerated in this trial, with most adverse events being of mild or moderate severity. The overall tolerability profile of sublingual zolpidem was similar to that of oral zolpidem...
  6. ncbi request reprint Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels
    Gillian M Keating
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 65:521-36. 2005
    ..If a decision is made to treat, combination therapy with peginterferon alpha-2a (40KD) plus ribavirin can be considered a first-line treatment option...
  7. doi request reprint Eprosartan: a review of its use in hypertension
    Greg L Plosker
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 69:2477-99. 2009
    ..Therefore, eprosartan is a useful treatment option in the management of a broad range of patients with hypertension, and its use with HCTZ provides a rational combination regimen...
  8. ncbi request reprint Dabigatran etexilate
    Mark Sanford
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 68:1699-709. 2008
    ..In patients undergoing total hip or total knee replacement surgery, there was no significant difference between dabigatran etexilate and enoxaparin sodium recipients in the incidence of major or minor bleeding...
  9. ncbi request reprint Selegiline transdermal system in major depressive disorder: profile report
    James E Frampton
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 21:521-4. 2007
  10. ncbi request reprint Zolpidem extended-release
    Marit D Moen
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    CNS Drugs 20:419-26; discussion 427-8. 2006
    ..Zolpidem CR was generally well tolerated and appears to have a tolerability profile similar to that of the original formulation of zolpidem...
  11. ncbi request reprint Amisulpride: a review of its use in the management of schizophrenia
    Kate McKeage
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:933-56. 2004
    ..Thus, amisulpride is an effective and well tolerated option for the first-line treatment of patients with acute schizophrenia as well as for those requiring long-term maintenance therapy...
  12. ncbi request reprint Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases
    Kate McKeage
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 26:251-68. 2008
    ....
  13. ncbi request reprint Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea)
    Risto S Cvetkovic
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:935-54. 2007
    ..Overall, adjunctive therapy with exenatide is a valuable therapeutic option in patients with type 2 diabetes requiring moderate improvements in glycaemic control despite treatment with metformin and/or a sulfonylurea...
  14. ncbi request reprint Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer
    Mark Sanford
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1319-40. 2008
    ..However, the evidence to date establishes anastrozole as a valuable adjuvant and extended adjuvant treatment for postmenopausal women with hormone receptor-positive, early-stage breast cancer...
  15. ncbi request reprint Pioglitazone: a review of its use in type 2 diabetes mellitus
    John Waugh
    Adis International Limited, Auckland, New Zealand
    Drugs 66:85-109. 2006
    ..Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes...
  16. ncbi request reprint Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:413-32. 2005
    ..Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication...
  17. ncbi request reprint Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 22:389-411. 2004
    ..Three cost-effectiveness analyses, all of which are modelled studies published as abstracts and/or posters, have been conducted with repaglinide in patients with type 2 diabetes. (ABSTRACT TRUNCATED)..
  18. doi request reprint Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Vicki Oldfield
    Wolters Kluwer Health Adis, North Shore, Auckland, New Zealand
    BioDrugs 23:125-35. 2009
    ..The tolerability profile of golimumab was generally consistent with that of other anti-TNF agents...
  19. ncbi request reprint Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 25:1031-53. 2007
    ..Although a clear pattern is not evident from available data, intuitively, the value of atorvastatin would be expected to increase with the patient's risk for serious cardiovascular events...
  20. ncbi request reprint Paliperidone extended release
    Lily P H Yang
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 21:417-25; discussion 426-7. 2007
    ..black triangle Paliperidone ER 3-12 mg/day for 6 weeks was generally well tolerated by patients with schizophrenia in clinical trials...
  21. ncbi request reprint Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis
    David R Goldsmith
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:85-104. 2008
    ..Sevelamer treatment was generally as well tolerated as calcium acetate or calcium carbonate treatment. Overall, sevelamer is a valuable option for the management of hyperphosphataemia in patients with ESRD on haemodialysis...
  22. ncbi request reprint Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1877-99. 2008
    ..As such, fixed-dose combinations of telmisartan/HCTZ provide an effective, rational and generally well tolerated treatment option for the management of patients with hypertension...
  23. ncbi request reprint Entecavir: a review of its use in chronic hepatitis B
    Dean M Robinson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1605-22; discussion 1623-4. 2006
    ..In addition, the tolerability profile of entecavir was generally similar to that of lamivudine. Thus, entecavir is a primary option in the treatment of chronic HBV infection in both nucleoside-naive and lamivudine-refractory patients...
  24. ncbi request reprint Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women
    Susan M Cheer
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2639-55. 2005
    ....
  25. ncbi request reprint Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer
    Greg L Plosker
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    BioDrugs 20:259-62. 2006
    ..Thus, trastuzumab is also rapidly becoming a standard component of adjuvant therapy for patients with HER2-positive early-stage breast cancer...
  26. ncbi request reprint Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation
    Natalie J Carter
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Drugs 73:715-39. 2013
    ..Thus, rivaroxaban is a reasonable alternative to warfarin for the prevention of stroke and systemic embolism in patients with NVAF...
  27. ncbi request reprint Extended-release intramuscular naltrexone in alcohol dependence in adults: profile report
    Tracy Swainston Harrison
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 21:83-7. 2007
  28. doi request reprint A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use
    Gillian M Keating
    Adis, Auckland, New Zealand
    BioDrugs 26:425-30. 2012
    ..In general, adverse events observed in clinical immunogenicity studies with a whole virions H5N1 vaccine (A/Vietnam/1203/2004) were similar to those reported with non-adjuvanted, inactivated, split virion seasonal influenza vaccines...
  29. ncbi request reprint Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation
    David Murdoch
    Adis International Limited, Auckland, New Zealand
    Drugs 66:671-92. 2006
    ....
  30. ncbi request reprint Omalizumab: a review of its use in the treatment of allergic asthma
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 22:189-204. 2008
    ..In addition, international treatment guidelines acknowledge the importance of omalizumab as a treatment option in these difficult-to-treat patient populations...
  31. ncbi request reprint Irbesartan: a review of its use in hypertension and diabetic nephropathy
    Katherine F Croom
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1543-69. 2008
    ..In addition, irbesartan was generally well tolerated in clinical trials. Thus, irbesartan is a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy...
  32. doi request reprint Tocilizumab: a review of its use in the management of rheumatoid arthritis
    Vicki Oldfield
    Wolters Kluwer Health, Auckland, New Zealand
    Drugs 69:609-32. 2009
    ..However, the present data suggest that tocilizumab is an important emerging treatment option in adult patients with moderate to severe rheumatoid arthritis...
  33. doi request reprint Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma
    Greg L Plosker
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:2645-60. 2008
    ....
  34. ncbi request reprint Zolpidem extended release in insomnia: profile report
    Marit D Moen
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs Aging 23:843-6. 2006
  35. ncbi request reprint Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 23:1057-72. 2005
    ....
  36. ncbi request reprint Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer
    Paul L McCormack
    Adis International Limited, Auckland, New Zealand
    Drugs 66:711-28. 2006
    ....
  37. ncbi request reprint Lubiprostone
    Kate McKeage
    Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:873-9. 2006
    ..Nausea was the most common adverse event, occurring in up to 31% of patients receiving lubiprostone...
  38. ncbi request reprint Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2823-43. 2004
    ..In general, the tolerability profile of peginterferon-alpha-2a plus ribavirin in APRICOT was similar to that previously reported in patients with HCV mono-infection...
  39. ncbi request reprint Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction
    Gillian M Keating
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2689-707. 2004
    ..Thus, the addition of eplerenone to standard medical therapy is an important new strategy for further improving mortality and morbidity in post-MI patients with LV systolic dysfunction and heart failure...
  40. ncbi request reprint Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Pharmacoeconomics 24:709-26. 2006
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of clopidogrel plus aspirin for up to 1 year as a cost-effective treatment relative to aspirin alone in this patient population...
  41. ncbi request reprint Spotlight on enoxaparin in ST-segment elevation myocardial infarction
    Natalie J Carter
    Wolters Kluwer Health Adis, 41 Centorian Drive, Mairangi Bay, Auckland, New Zealand
    BioDrugs 22:343-5. 2008
    ..75 mg/kg; the dose was also reduced to 1 mg/kg every 24 hours in patients of any age who had an estimated creatinine clearance of <30 mL/min. Data from several earlier randomized, multicentre, phase III trials support these results...
  42. ncbi request reprint Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension
    Greg L Plosker
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Pharmacoeconomics 24:1249-72. 2006
    ....
  43. ncbi request reprint Galantamine extended release in Alzheimer's disease: profile report
    Dean M Robinson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs Aging 23:839-42. 2006
  44. ncbi request reprint Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension
    Risto S Cvetkovic
    Adis International Limited, Auckland, New Zealand
    Drugs 65:1851-68. 2005
    ..In addition, a fixed, low-dose combination of ramipril/felodipine ER is a potential alternative to monotherapy for the initial management of essential hypertension...
  45. ncbi request reprint Sulfasalazine: a review of its use in the management of rheumatoid arthritis
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 65:1825-49. 2005
    ..Based on considerations of safety, convenience and cost, many rheumatologists (particularly outside of the US) select sulfasalazine as initial therapy, although preferred first-line treatment options vary between countries...
  46. ncbi request reprint Imatinib: a review of its use in chronic myeloid leukaemia
    Marit D Moen
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:299-320. 2007
    ..It remains a valuable treatment for all stages of the disease, especially initial treatment of newly diagnosed Ph+ chronic-phase CML, and is endorsed by European and US treatment guidelines as a first-line option...
  47. ncbi request reprint Amlodipine/Valsartan: fixed-dose combination in hypertension
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:373-81. 2008
    ..Amlodipine/valsartan was generally well tolerated in clinical trials. In particular, the incidence of peripheral oedema was significantly lower in patients receiving amlodipine/valsartan than in those treated with amlodipine monotherapy...
  48. ncbi request reprint Spotlight on the pharmacoeconomics of escitalopram in depression
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:469-73. 2004
    ..In the prospective analysis, escitalopram had lower estimated drug acquisition costs than venlafaxine XR...
  49. ncbi request reprint Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents
    Paul L McCormack
    Adis International Limited, Auckland, New Zealand
    Drugs 66:1151-68. 2006
    ..The drug is well tolerated, with low systemic bioavailability and minimal systemic activity. Therefore, it is an effective and convenient option for controller therapy of persistent asthma in adults and adolescents...
  50. ncbi request reprint Oral fludarabine
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 63:2317-23. 2003
    ..Overall, the tolerability profile of oral fludarabine is similar to that of the intravenous formulation...
  51. ncbi request reprint Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:397-401. 2004
    ..This also means repeat prescriptions during long-term treatment can be more conveniently processed...
  52. ncbi request reprint Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 23:945-64. 2005
    ..Healthcare resource use studies and pharmacoeconomic analyses generally support the use of linezolid in some subgroups of patients, although results should be interpreted with due consideration of the study limitations...
  53. doi request reprint Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis
    James E Frampton
    Wolters Kluwer Health Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 10:51-72. 2009
    ....
  54. ncbi request reprint Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 23:193-206. 2005
    ....
  55. ncbi request reprint Novolizer: a multidose dry powder inhaler
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 63:2437-45; discussion 2447-8. 2003
    ..Most patients preferred it to previously used MDIs or DPIs. Only 4-5% found the taste feedback unacceptable. Physicians observed improved compliance over 4 weeks in 80% of patients with asthma using Novolizer...
  56. ncbi request reprint Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1839-47. 2004
    ..The most frequently reported grade 3-4 adverse events with paclitaxel administered sequentially to AC were haematological events (neutropenia, thrombocytopenia, anaemia) and nausea/vomiting...
  57. doi request reprint Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:2535-51. 2008
    ..Pegylated liposomal doxorubicin plus bortezomib is now established as an additional standard of care in the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy...
  58. ncbi request reprint Galantamine extended release
    Dean M Robinson
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 20:673-81; discussion 682-3. 2006
    ..Adverse events occurred in similar proportions of galantamine ER, galantamine IR and placebo recipients...
  59. ncbi request reprint Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 66:449-75. 2006
    ..Thus, trastuzumab is also rapidly becoming a standard component of adjuvant therapy for patients with HER2-positive early-stage breast cancer...
  60. ncbi request reprint Tipranavir
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 63:1611-8. 2003
    ..In general, tipranavir has been well tolerated in clinical trials. As with other protease inhibitors, the most common adverse events with tipranavir have been gastrointestinal disturbances...
  61. ncbi request reprint Fondaparinux: use in thromboprophylaxis of acute medical patients
    Sohita Dhillon
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs Aging 25:81-8. 2008
    ..Fondaparinux was generally well tolerated in this clinical trial. In patients receiving fondaparinux, the incidence of major bleeding was similar to that in patients receiving placebo and the incidence of minor bleeding was <3%...
  62. ncbi request reprint Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases
    Therese M Chapman
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 21:61-3. 2007
    ..In general, VSL#3 was well tolerated in clinical trials. Large, well designed, controlled confirmatory clinical trials will further determine the place of VSL#3 in the treatment of ulcerative colitis...
  63. ncbi request reprint Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX
    Katherine A Lyseng-Williamson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 25:1007-29. 2007
    ....
  64. doi request reprint Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery
    Sean T Duggan
    Wolters Kluwer Health, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 69:1829-51. 2009
    ..Although the position of rivaroxaban relative to other therapies remains to be fully determined, it is an effective emerging option for the prevention of VTE following THR and TKR...
  65. ncbi request reprint Nilotinib
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:449-59; discussion 460-1. 2008
    ..Adverse events reported with nilotinib have generally been of mild to moderate severity. Grade 3 or 4 neutropenia and thrombocytopenia were reported in 29% of patients each...
  66. doi request reprint Mirtazapine: a review of its use in major depression and other psychiatric disorders
    Katherine F Croom
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    CNS Drugs 23:427-52. 2009
    ..In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications...
  67. doi request reprint Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain
    Greg L Plosker
    Adis, Auckland, New Zealand
    CNS Drugs 26:367-73. 2012
    ..Transdermal buprenorphine has also shown analgesic efficacy in patients with chronic non-malignant pain of various causes...
  68. ncbi request reprint Duloxetine: a review of its use in the treatment of major depressive disorder
    James E Frampton
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    CNS Drugs 21:581-609. 2007
    ..It also appears to be an attractive option for MDD patients presenting with painful physical symptoms...
  69. ncbi request reprint Retigabine: in partial seizures
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 20:601-8; discussion 609-10. 2006
    ..Across all three retigabine groups in the large phase II trial, somnolence (20.3%), dizziness (14.6%), confusion (12.3%) and speech disorder (11.3%) were the most frequent CNS-related adverse events...
  70. ncbi request reprint Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease
    Greg L Plosker
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 29:807-21. 2011
    ..Future cost-effectiveness analyses with cinacalcet should incorporate data on hard clinical outcomes from the EVOLVE study once this information becomes available...
  71. doi request reprint Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years)
    Sean T Duggan
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 27:597-605. 2010
    ....
  72. doi request reprint Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis
    Sheridan M Hoy
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1319-47. 2010
    ..Thus, available data indicate that tinzaparin sodium is a useful option in the prevention and treatment of DVT and/or PE, and in maintaining the patency of haemodialysis circuits in adult patients...
  73. doi request reprint A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®]
    Greg L Plosker
    Adis, Auckland, New Zealand
    Drugs 72:1543-57. 2012
    ..In general, adverse events observed in clinical immunogenicity studies with H5N1 vaccine (A/Vietnam/1203/2004) were similar to those reported with non-adjuvanted, inactivated, seasonal influenza vaccines...
  74. doi request reprint Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension
    Claudine M Baldwin
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:833-41. 2009
    ..Aliskiren/HCTZ was generally well tolerated in clinical trials, with most adverse events being mild and transient in nature...
  75. doi request reprint Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology
    Jamie D Croxtall
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 69:339-59. 2009
    ..Sertaconazole administered as a vaginal suppository was generally associated with an absence of adverse events and, where reported, included only local irritation after insertion...
  76. ncbi request reprint Escitalopram: a review of its use in the management of anxiety disorders
    Sohita Dhillon
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    CNS Drugs 20:763-90. 2006
    ..Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD...
  77. ncbi request reprint Nomegestrol acetate/estradiol: in oral contraception
    Lily P H Yang
    Adis, Auckland, New Zealand
    Drugs 72:1917-28. 2012
    ..Overall, compared with drospirenone/ethinylestradiol, nomegestrol acetate/estradiol appeared to be associated with less favourable acne-related outcomes, and shorter, lighter or absent periods...
  78. ncbi request reprint Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus
    Natalie J Carter
    Wolters Kluwer Health Adis, 41 Centorian Drive, Mairangi Bay, Auckland, New Zealand
    BioDrugs 22:279-92. 2008
    ..As a result, stockpiling AS03-H5N1 vaccine has the potential to protect populations against a pandemic caused by an influenza A/H5N1 virus and may represent an important measure in pandemic preparedness...
  79. doi request reprint Quetiapine: a pharmacoeconomic review of its use in bipolar disorder
    Greg L Plosker
    Adis, Auckland, New Zealand
    Pharmacoeconomics 30:611-31. 2012
    ....
  80. doi request reprint Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain
    Greg L Plosker
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:2491-509. 2011
    ....
  81. doi request reprint Cladribine tablets: in relapsing-remitting multiple sclerosis
    Victoria J Muir
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 25:239-49. 2011
    ..Lymphocytopenia, herpes zoster infections and neoplasms (including malignancies) were more common in cladribine than placebo recipients...
  82. doi request reprint Sipuleucel-T: in metastatic castration-resistant prostate cancer
    Greg L Plosker
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:101-8. 2011
    ..The most common adverse events (e.g. infusion-related events, such as chills and fever) generally occurred within the first day after administration of sipuleucel-T and resolved within 2 days...
  83. doi request reprint Cerebrolysin: a review of its use in dementia
    Greg L Plosker
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 26:893-915. 2009
    ....
  84. doi request reprint Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]
    Sean T Duggan
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:115-22. 2009
    ..fig: see text]..
  85. ncbi request reprint Enoxaparin: a review of its use in ST-segment elevation myocardial infarction
    Natalie J Carter
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:691-710. 2008
    ..Data from several earlier randomized, multicentre, phase III trials support these results...
  86. doi request reprint Insulin glulisine: a review of its use in the management of diabetes mellitus
    Karly P Garnock-Jones
    Wolters Kluwer Health Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 69:1035-57. 2009
    ..Thus, insulin glulisine is an effective and well tolerated option for the treatment of patients with type 1 and type 2 diabetes...